Literature DB >> 25248296

Malignant glaucoma after cataract surgery.

Devesh K Varma1, Graham W Belovay2, Diamond Y Tam2, Iqbal Ike K Ahmed2.   

Abstract

PURPOSE: To report a series of eyes that developed malignant glaucoma after cataract surgery.
SETTING: Private academic practice, Toronto, Ontario, Canada.
DESIGN: Retrospective case series.
METHODS: Eyes that developed malignant glaucoma after cataract surgery were treated with medical therapy. This was followed by laser iridozonulohyaloidotomy, anterior chamber reformation and intraocular lens (IOL) pushback, and finally with surgical iridozonulohyaloidovitrectomy if all other measures were unsuccessful. Refraction, intraocular pressure (IOP), gonioscopy, and anterior chamber depth (ACD) by anterior segment optical coherence tomography were analyzed before treatment and after treatment.
RESULTS: The study evaluated 20 eyes of 18 female patients aged 44 to 86 years. Preoperatively, the mean refraction was +3.11 diopters (D) ± 2.89 (SD), the mean axial length was 21.30 ± 1.40 mm, and all eyes had narrow or closed angles. Malignant glaucoma was diagnosed a mean of 5.8 ± 7.1 weeks postoperatively. At diagnosis, the mean refraction was -2.15 ± 2.95 D; the mean ACD, 2.49 ± 0.72 mm; and the mean IOP, 28.3 ± 10.8 mm Hg on a mean of 1.3 ± 1.6 medications. Two eyes responded to cycloplegia, 7 to laser iridozonulohyaloidotomy, and 6 to anterior chamber reformation-IOL pushback; 5 eyes required vitrectomy. Posttreatment, the mean refraction was -0.56 ± 1.07 D; the mean ACD, 3.30 ± 0.50 mm; and the mean IOP, 14.4 ± 4.60 mm Hg on a mean of 1.2 ± 1.4 medications. Cycloplegia was discontinued in 17 eyes.
CONCLUSION: Malignant glaucoma can occur after phacoemulsification and presents with myopic surprise, anterior chamber shallowing and, possibly, elevated IOP. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
Copyright © 2014 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248296     DOI: 10.1016/j.jcrs.2014.02.045

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

1.  Surgical management of malignant glaucoma: a retrospective analysis of fifty eight eyes.

Authors:  S Balekudaru; N S Choudhari; P Rewri; R George; P S Bhende; M Bhende; V Lingam; G Lingam
Journal:  Eye (Lond)       Date:  2017-03-03       Impact factor: 3.775

2.  Intraoperative malignant glaucoma during femtosecond laser-assisted cataract surgery: A case report.

Authors:  Rong Xu; Danmin Cao; Ya Jiao; Qingyan Zeng
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

3.  Application of Nd:YAG laser to the anterior vitreous in malignant glaucoma - a systemic review and meta-analysis.

Authors:  Margarita Safir; Idan Hecht; Tal Sharon; Adi Einan-Lifshitz; Avner Belkin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-29       Impact factor: 3.535

4.  Seasonal Variation in the Incidence of Malignant Glaucoma after Cataract Surgery.

Authors:  Thomas S Shute; Devesh K Varma; Diamond Tam; Thomas Klein; Prima Moinul; Iqbal Ike K Ahmed; Arsham Sheybani
Journal:  J Ophthalmic Vis Res       Date:  2019 Jan-Mar

Review 5.  Acute and chronic fluid misdirection syndrome: pathophysiology and treatment.

Authors:  Andrzej Grzybowski; Piotr Kanclerz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-11-06       Impact factor: 3.535

6.  Clinical Characteristics and Outcomes of Malignant Glaucoma after Different Procedures Treated with Pars Plana Vitrectomy: A 10-Year Retrospective Study.

Authors:  Lina Krėpštė; Reda Žemaitienė; Arūnas Miliauskas
Journal:  Medicina (Kaunas)       Date:  2018-09-05       Impact factor: 2.430

7.  [Chronification of malignant glaucoma after cataract surgery].

Authors:  Cornelius Wiedenmann; Stefaniya Boneva; Alexandra Anton; Thomas Reinhard; Jan Lübke
Journal:  Ophthalmologe       Date:  2021-02       Impact factor: 1.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.